Akero Therapeutics scores $65 mln Series A
Cambridge, Massachusetts-based Akero Therapeutics Inc, a biotechnology company focused on treating non-alcoholic steatohepatitis and other serious metabolic diseases, has raised $65 million in Series A financing. Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures led the round.
25 June 2018•1 min read
